191 related articles for article (PubMed ID: 16912163)
1. Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression.
Ai L; Kim WJ; Kim TY; Fields CR; Massoll NA; Robertson KD; Brown KD
Cancer Res; 2006 Aug; 66(16):7899-909. PubMed ID: 16912163
[TBL] [Abstract][Full Text] [Related]
2. Cystatin M expression is reduced in gastric carcinoma and is associated with promoter hypermethylation.
Chen X; Cao X; Dong W; Xia M; Luo S; Fan Q; Xie J
Biochem Biophys Res Commun; 2010 Jan; 391(1):1070-4. PubMed ID: 20004178
[TBL] [Abstract][Full Text] [Related]
3. Frequent epigenetic inactivation of cystatin M in breast carcinoma.
Schagdarsurengin U; Pfeifer GP; Dammann R
Oncogene; 2007 May; 26(21):3089-94. PubMed ID: 17099723
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer.
Ai L; Tao Q; Zhong S; Fields CR; Kim WJ; Lee MW; Cui Y; Brown KD; Robertson KD
Carcinogenesis; 2006 Jul; 27(7):1341-8. PubMed ID: 16501252
[TBL] [Abstract][Full Text] [Related]
5. [Epigenetic inactivation of microRNA genes in mammary carcinoma].
Lehmann U; Hasemeier B; Römermann D; Müller M; Länger F; Kreipe H
Verh Dtsch Ges Pathol; 2007; 91():214-20. PubMed ID: 18314617
[TBL] [Abstract][Full Text] [Related]
6. Cystatin m: a novel candidate tumor suppressor gene for breast cancer.
Zhang J; Shridhar R; Dai Q; Song J; Barlow SC; Yin L; Sloane BF; Miller FR; Meschonat C; Li BD; Abreo F; Keppler D
Cancer Res; 2004 Oct; 64(19):6957-64. PubMed ID: 15466187
[TBL] [Abstract][Full Text] [Related]
7. Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions.
Rivenbark AG; Livasy CA; Boyd CE; Keppler D; Coleman WB
Exp Mol Pathol; 2007 Oct; 83(2):188-97. PubMed ID: 17540367
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis.
Veeck J; Geisler C; Noetzel E; Alkaya S; Hartmann A; Knüchel R; Dahl E
Carcinogenesis; 2008 May; 29(5):991-8. PubMed ID: 18356147
[TBL] [Abstract][Full Text] [Related]
9. The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer.
Ai L; Kim WJ; Demircan B; Dyer LM; Bray KJ; Skehan RR; Massoll NA; Brown KD
Carcinogenesis; 2008 Mar; 29(3):510-8. PubMed ID: 18174247
[TBL] [Abstract][Full Text] [Related]
10. Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells.
Shridhar R; Zhang J; Song J; Booth BA; Kevil CG; Sotiropoulou G; Sloane BF; Keppler D
Oncogene; 2004 Mar; 23(12):2206-15. PubMed ID: 14676833
[TBL] [Abstract][Full Text] [Related]
11. Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas.
Kobatake T; Yano M; Toyooka S; Tsukuda K; Dote H; Kikuchi T; Toyota M; Ouchida M; Aoe M; Date H; Pass HI; Doihara H; Shimizu N
Oncol Rep; 2004 Nov; 12(5):1087-92. PubMed ID: 15492797
[TBL] [Abstract][Full Text] [Related]
12. Biallelic inactivation of the thyroid hormone receptor beta1 gene in early stage breast cancer.
Li Z; Meng ZH; Chandrasekaran R; Kuo WL; Collins CC; Gray JW; Dairkee SH
Cancer Res; 2002 Apr; 62(7):1939-43. PubMed ID: 11929806
[TBL] [Abstract][Full Text] [Related]
13. Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas.
Qiu J; Ai L; Ramachandran C; Yao B; Gopalakrishnan S; Fields CR; Delmas AL; Dyer LM; Melnick SJ; Yachnis AT; Schwartz PH; Fine HA; Brown KD; Robertson KD
Lab Invest; 2008 Sep; 88(9):910-25. PubMed ID: 18607344
[TBL] [Abstract][Full Text] [Related]
14. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
[TBL] [Abstract][Full Text] [Related]
15. Concordant epigenetic silencing of transforming growth factor-beta signaling pathway genes occurs early in breast carcinogenesis.
Hinshelwood RA; Huschtscha LI; Melki J; Stirzaker C; Abdipranoto A; Vissel B; Ravasi T; Wells CA; Hume DA; Reddel RR; Clark SJ
Cancer Res; 2007 Dec; 67(24):11517-27. PubMed ID: 18089780
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional silencing of hedgehog-interacting protein by CpG hypermethylation and chromatic structure in human gastrointestinal cancer.
Taniguchi H; Yamamoto H; Akutsu N; Nosho K; Adachi Y; Imai K; Shinomura Y
J Pathol; 2007 Oct; 213(2):131-9. PubMed ID: 17724792
[TBL] [Abstract][Full Text] [Related]
17. Expression analysis of cystatin C and M in laser-capture microdissectioned human breast cancer cells--a preliminary study.
Vigneswaran N; Wu J; Muller S; Zacharias W; Narendran S; Middleton L
Pathol Res Pract; 2005; 200(11-12):753-62. PubMed ID: 15792117
[TBL] [Abstract][Full Text] [Related]
18. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer.
Umbricht CB; Evron E; Gabrielson E; Ferguson A; Marks J; Sukumar S
Oncogene; 2001 Jun; 20(26):3348-53. PubMed ID: 11423985
[TBL] [Abstract][Full Text] [Related]
19. Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer.
Nass SJ; Herman JG; Gabrielson E; Iversen PW; Parl FF; Davidson NE; Graff JR
Cancer Res; 2000 Aug; 60(16):4346-8. PubMed ID: 10969774
[TBL] [Abstract][Full Text] [Related]
20. Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer.
Fujii H; Biel MA; Zhou W; Weitzman SA; Baylin SB; Gabrielson E
Oncogene; 1998 Apr; 16(16):2159-64. PubMed ID: 9572497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
